1. What Is the Brachytherapy Market?
The Brachytherapy Market covers the cancer treatment technique that places the radioactive source within or immediately adjacent to the tumour tissue to deliver the high local radiation dose from the short-range radiation emission. The short-range emission achieves the steep dose gradient that protects the adjacent normal structures from the dose that the high dose rate within the implant volume achieves for the tumour. Brachytherapy sources include the iridium-192 high-dose-rate source used in the intracavitary and interstitial applications for cervical, endometrial, breast, and prostate cancer. The iodine-125 and palladium-103 low-dose-rate seeds are permanently implanted in the prostate for the low-risk prostate cancer. The caesium-137 and ruthenium sources are used in the ocular brachytherapy for the uveal melanoma. The brachytherapy market has experienced the pressure from the expansion of the external beam SBRT and IMRT that have displaced brachytherapy in several indications. The non-invasive external beam alternative provides the physician and patient preference over the applicator placement and the hospital stay that intracavitary brachytherapy requires. Cervical cancer brachytherapy maintains the superiority that the EMBRACE studies have demonstrated for the adaptive intracavitary and interstitial brachytherapy that achieves higher local control than the IMRT alternative.
2. Brachytherapy Market Size & Forecast
3. Emerging Technologies
- Image-guided adaptive brachytherapy for cervical cancer uses the MRI at the time of the brachytherapy insertion to define the current extent of the residual tumour after the external beam chemoradiation. The MRI optimises the dose distribution to the MRI-defined clinical target volume. The technique achieves the 90 to 95 percent local control at 3 years in the EMBRACE-I and EMBRACE-II data that provides the definitive evidence for the superiority over the MRI-based IMRT alone.
- High-dose-rate prostate brachytherapy boost delivers the focal high dose to the prostate using the interstitial needles and the iridium-192 HDR source as the dose escalation complement to the external beam IMRT. The radiobiological benefit of the high dose per fraction that the prostate cancer alpha/beta ratio of 2 suggests provides the superior tumour control. The HDR boost dose escalates beyond the lower dose per fraction of the conventional fractionated EBRT.
- Prostate seed permanent implant LDR brachytherapy uses the iodine-125 or palladium-103 seeds implanted transperineally under transrectal ultrasound guidance. The single-visit outpatient prostate cancer treatment serves the low and favourable intermediate-risk prostate cancer. The technique achieves the 10-year biochemical control of 90 to 95 percent that equals or exceeds the surgical prostatectomy without the urinary incontinence and erectile dysfunction that the surgical approach more frequently produces.
- Intravascular brachytherapy historical use for the in-stent restenosis prevention preceded the drug-eluting stent that replaced the beta and gamma radiation source. The PREVENT and SVG WRIST trials demonstrated the radiation source could reduce the restenosis rate after bare metal coronary stent placement. The intravascular brachytherapy is no longer commercially available as the drug-eluting stent has achieved the same outcome pharmacologically.
Comparable technologies are influencing adjacent market segments in similar ways. Read more in our Stereotactic Radiosurgery Market.
4. Key Market Opportunity
Substantial growth potential in the Brachytherapy market involves MR-guided adaptive brachytherapy expansion in cervical and endometrial cancer, where image guidance enables personalised dose optimisation improving local control in the high-burden cervical cancer indication globally. Vendors with MR-compatible afterloader systems capture this adaptive brachytherapy premium. Adjacent demand centers on combined EBRT and HDR brachytherapy boost in high-risk prostate cancer. As MR-guided adaptive brachytherapy expands and prostate boost programmes grow, the addressable opportunity is sustaining brachytherapy volume through precision delivery improvements and prostate high-risk application.
5. Top Companies in the Brachytherapy Market
The following organisations hold leading positions in the Brachytherapy Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Elekta
- Varian Medical Systems
- Eckert and Ziegler
- BEBIG Medical
- iCAD
- Theragenics
- Cianna Medical (Hologic)
6. Market Segmentation
The Brachytherapy Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Source | LDR HDR Electronic |
| By Indication | Cervical Prostate Breast Endometrial Skin |
| By System | Afterloader Seeds Electronic Brachytherapy |
| By Geography | North America The U.S. Canada Europe The UK Germany France Italy Spain Denmark Netherlands Finland Sweden Norway Russia Austria Poland Rest of Europe Asia Pacific China Japan India South Korea Australia Indonesia Vietnam Philippines Singapore Taiwan Thailand Rest of Asia Pacific Latin America Brazil Mexico Argentina Rest of South America Middle East and Africa GCC Countries Israel South Africa Rest of Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Brachytherapy Market trajectory over the forecast period:
MRI-Guided Adaptive Cervical Cancer Brachytherapy Achieving 90 to 95 Percent 3-Year Local Control in EMBRACE-I and EMBRACE-II Has Provided the Definitive Evidence That Adaptive Intracavitary Brachytherapy Is Superior to MRI-Based IMRT for the Bulky Residual Cervical Tumour.Iodine-125 and palladium-103 permanent seed implantation achieves 15-year biochemical disease-free survival rates of 85-92% in low-risk and 74-82% in intermediate-risk prostate cancer in published institutional series, with late urinary and rectal toxicity rates equivalent to or lower than external beam radiotherapy in head-to-head quality-of-life comparisons. The outpatient single procedure completed in 90 minutes compares favourably with the six to nine weeks of daily external beam treatment, and the prostate brachytherapy dose distribution is fundamentally more conformal than any photon EBRT technique due to the source's intraprostatic position. Competition from SBRT at 5-fraction and robotic prostatectomy has displaced brachytherapy from its prior position as the preferred monotherapy for low-risk prostate cancer, but the HDR boost combination with EBRT has maintained brachytherapy's clinical relevance in intermediate and high-risk disease.
HDR Prostate Brachytherapy Boost Delivering High Dose Per Fraction Exploiting the Prostate α/β Ratio of 2 Provides the Radiobiological Dose Escalation Advantage Over Conventionally Fractionated EBRT That the Favourable Hypofractionation Response of Prostate Cancer Supports.Intracavitary brachytherapy boost following external beam radiotherapy and concurrent cisplatin achieves 3-year local control rates of 91% in cervical cancer compared with significantly inferior results when external beam radiotherapy alone is used without brachytherapy boost, and the EMBRACE I and II studies have established modern image-guided adaptive brachytherapy as the technical standard. MR-guided brachytherapy using rotating shields and MR-compatible applicators from Elekta enables dose painting within the cervical target that conventional 2D radiographic brachytherapy planning cannot achieve, reducing the normal-tissue dose to bladder and rectum that historically limited treatment intensification. The clinical urgency of maintaining brachytherapy access in gynaecological oncology is heightened by evidence that EBRT boost alone for locally advanced cervical cancer results in approximately 20% lower local control than proper brachytherapy boost delivery.
Prostate Seed LDR Brachytherapy Single-Visit Outpatient Treatment Achieving 90 to 95 Percent 10-Year Biochemical Control With Lower Incontinence and ED Rates Than Surgical Prostatectomy Demonstrates Why Brachytherapy Retains the Role in Low and Favourable Intermediate Risk Disease.Xoft's Axxent electronic brachytherapy system delivers therapeutic radiation from a miniaturised X-ray tube that generates low-energy photons at the applicator tip without requiring sealed radioactive sources, eliminating the regulatory burden and isotope logistics associated with iridium-192 and ytterbium-169 HDR brachytherapy. The technology has found application in skin cancer, partial breast irradiation, and endocavitary rectal cancer treatment where the surface-dose profile of low-energy photons is clinically appropriate. The 2022 closure of Xoft parent company iCAD's brachytherapy division created a market gap that Sensus Healthcare and new entrant platforms are attempting to fill with commercial electronic brachytherapy systems optimised for dermatology and superficial cancer applications.
For related market intelligence, see the Radiotherapy Market.
8. Segmental Analysis
By source, the high-dose-rate segment dominated the Brachytherapy Market in 2025, as iridium-192 afterloading systems from Elekta and Varian Medical Systems anchored gynaecological and prostate treatment delivery, generating the largest share of brachytherapy procedures performed worldwide.
By indication, the prostate cancer segment is projected to register the highest growth rate through 2034, as focal and boost brachytherapy combined with external-beam radiotherapy gains adoption for intermediate and high-risk disease, offering dose escalation with lower toxicity than alternative approaches in a large patient population.
9. Regional Analysis
Regional demand patterns across the Brachytherapy Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the Brachytherapy Market in 2025, accounting for approximately 45% of global revenue, attributed to the large number of academic and community centres performing HDR and LDR brachytherapy and the established US prostate brachytherapy practice. Moreover, MR-guided adaptive brachytherapy adoption is advancing in North American academic gynaecology oncology. In addition, electronic brachytherapy for skin cancer sustains demand. Regional dominance is due to this combination of centre density and indication breadth.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the Brachytherapy Market through 2034, driven by the high cervical cancer burden in China, India, and Southeast Asia requiring brachytherapy as standard curative treatment and the investment in gynaecological oncology radiotherapy infrastructure. The region is also witnessing prostate brachytherapy adoption growing. Moreover, the large cervical cancer patient population sustains brachytherapy procedure volume. The combination of these demand drivers and cervical cancer burden positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Brachytherapy Market was valued at USD 936.30 Mn in 2025 and is projected to reach USD 1,555.20 Mn by 2034, growing at a CAGR of 5.8% over the 2026–2034 forecast period.
The Brachytherapy Market is projected to grow at a CAGR of 5.8% from 2026 to 2034.
North America dominated the Brachytherapy Market in 2025, accounting for approximately 45% of global revenue, attributed to the large number of academic and community centres performing HDR and LDR brachytherapy and the established US prostate brachytherapy practice.
The leading companies in the Brachytherapy Market include Elekta, Varian Medical Systems, Eckert and Ziegler, BEBIG Medical, iCAD, Theragenics, Cianna Medical (Hologic).
Mri-guided adaptive cervical cancer brachytherapy achieving 90 to 95 percent 3-year local control in embrace-i and embrace-ii has provided the definitive evidence that adaptive intracavitary brachytherapy is superior to mri-based imrt for the bulky residual cervical tumour.
By source, the high-dose-rate segment dominated the Brachytherapy Market in 2025, as iridium-192 afterloading systems from Elekta and Varian Medical Systems anchored gynaecological and prostate treatment delivery, generating the largest share of brachytherapy procedures performed worldwide.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.